ME Fundamental Analysis - 23ANDME HOLDING CO -CLASS A

Fundamental Rating

ME gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. ME scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ME has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ME had negative earnings in the past year.
In the past year ME has reported a negative cash flow from operations.
In the past 5 years ME always reported negative net income.
ME had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ME has a Return On Assets of -138.01%. This is amonst the worse of the industry: ME underperforms 93.64% of its industry peers.
Looking at the Return On Equity, with a value of -545.25%, ME is doing worse than 86.36% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-138.01%
ROE	-545.25%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 52.58%, ME is in the better half of the industry, outperforming 78.18% of the companies in the same industry.
In the last couple of years the Gross Margin of ME has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ME so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	52.58%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.93%

GM growth 5Y0.67%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ME does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -13.45, we must say that ME is in the distress zone and has some risk of bankruptcy.
ME has a worse Altman-Z score (-13.45) than 90.91% of its industry peers.
ME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-13.45

ROIC/WACCN/A

WACC8.71%

2.3 Liquidity

ME has a Current Ratio of 1.11. This is a normal value and indicates that ME is financially healthy and should not expect problems in meeting its short term obligations.
ME has a Current ratio of 1.11. This is in the lower half of the industry: ME underperforms 68.18% of its industry peers.
A Quick Ratio of 0.96 indicates that ME may have some problems paying its short term obligations.
ME has a Quick ratio of 0.96. This is in the lower half of the industry: ME underperforms 69.09% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.11
Quick Ratio	0.96

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ME have decreased strongly by -29.41% in the last year.
Looking at the last year, ME shows a very negative growth in Revenue. The Revenue has decreased by -15.83% in the last year.
ME shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.01% yearly.

EPS 1Y (TTM)-29.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-197.53%

Revenue 1Y (TTM)-15.83%

Revenue growth 3Y-3.43%

Revenue growth 5Y-13.01%

Sales Q2Q%34.67%

3.2 Future

ME is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.35% yearly.
The Revenue is expected to grow by 19.08% on average over the next years. This is quite good.

EPS Next Y-329.17%

EPS Next 2Y-99.49%

EPS Next 3Y25.35%

EPS Next 5YN/A

Revenue Next Year22.44%

Revenue Next 2Y19.85%

Revenue Next 3Y5.77%

Revenue Next 5Y19.08%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ME. In the last year negative earnings were reported.
Also next year ME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ME's earnings are expected to grow with 25.35% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-99.49%

EPS Next 3Y25.35%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ME does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

23ANDME HOLDING CO -CLASS A

NASDAQ:ME (3/28/2025, 8:00:00 PM)

After market: 0.5 -0.11 (-17.53%)

0.6063

-0.16 (-21.26%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)11-06 2024-11-06/amc

Earnings (Next)N/A N/A

Inst Owners24.69%

Inst Owner Change0%

Ins Owners9.89%

Ins Owner Change0%

Market Cap16.27M

Revenue(TTM)208.78M

Net Income(TTM)-382.87M

Analysts37.78

Price Target2.12 (249.66%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)-1.94%

Min Revenue beat(2)-5.66%

Max Revenue beat(2)1.78%

Revenue beat(4)2

Avg Revenue beat(4)-4.8%

Min Revenue beat(4)-24.62%

Max Revenue beat(4)9.3%

Revenue beat(8)4

Avg Revenue beat(8)-6%

Revenue beat(12)6

Avg Revenue beat(12)-3.09%

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-94.8%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0.06%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.08
P/FCF	N/A
P/OCF	N/A
P/B	0.23
P/tB	0.73
EV/EBITDA	N/A

EPS(TTM)-13.2

EYN/A

EPS(NY)-52.53

Fwd EYN/A

FCF(TTM)-6.05

FCFYN/A

OCF(TTM)-5.76

OCFYN/A

SpS7.78

BVpS2.62

TBVpS0.83

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-138.01%
ROE	-545.25%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	52.58%
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.93%

GM growth 5Y0.67%

F-Score4

Asset Turnover0.75

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	32.25%
Cap/Sales	3.65%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.11
Quick Ratio	0.96
Altman-Z	-13.45

F-Score4

WACC8.71%

ROIC/WACCN/A

Cap/Depr(3y)39.05%

Cap/Depr(5y)93.91%

Cap/Sales(3y)4.44%

Cap/Sales(5y)8.08%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-29.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-197.53%

EPS Next Y-329.17%

EPS Next 2Y-99.49%

EPS Next 3Y25.35%

EPS Next 5YN/A

Revenue 1Y (TTM)-15.83%

Revenue growth 3Y-3.43%

Revenue growth 5Y-13.01%

Sales Q2Q%34.67%

Revenue Next Year22.44%

Revenue Next 2Y19.85%

Revenue Next 3Y5.77%

Revenue Next 5Y19.08%

EBIT growth 1Y37.44%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year54.46%

EBIT Next 3Y21.64%

EBIT Next 5YN/A

FCF growth 1Y2.76%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y0.64%

OCF growth 3YN/A

OCF growth 5YN/A

23ANDME HOLDING CO -CLASS A / ME FAQ

Can you provide the ChartMill fundamental rating for 23ANDME HOLDING CO -CLASS A?

ChartMill assigns a fundamental rating of 2 / 10 to ME.

Can you provide the valuation status for 23ANDME HOLDING CO -CLASS A?

ChartMill assigns a valuation rating of 1 / 10 to 23ANDME HOLDING CO -CLASS A (ME). This can be considered as Overvalued.

Can you provide the profitability details for 23ANDME HOLDING CO -CLASS A?

23ANDME HOLDING CO -CLASS A (ME) has a profitability rating of 1 / 10.

Can you provide the expected EPS growth for ME stock?

The Earnings per Share (EPS) of 23ANDME HOLDING CO -CLASS A (ME) is expected to decline by -329.17% in the next year.

23ANDME HOLDING CO -CLASS A (ME) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

23ANDME HOLDING CO -CLASS A / ME FAQ

Can you provide the ChartMill fundamental rating for 23ANDME HOLDING CO -CLASS A?

Can you provide the valuation status for 23ANDME HOLDING CO -CLASS A?

Can you provide the profitability details for 23ANDME HOLDING CO -CLASS A?

Can you provide the expected EPS growth for ME stock?